Clinical Guidelines
Feature

EYP-1901 for Retinal Exudative Diseases

An overview of the current status of the EYP-1901 clinical trial program in wet AMD and DME, presented at Hawaiian Eye and Retina 2026

Share

  • 1

    EYP-1901 is an intravitreal insert for AMD and DME treatment.

  • 2

    Sustained release of vorolanib decreases treatment burden.

  • 3

    Phase 2 trials show noninferiority to aflibercept.

  • 4

    Ongoing Phase 3 trials are LUGANO and LUCIA.

  • 5

    Topline data expected mid-

  • 6

    EYP-1901 improved treatment intervals significantly.

  • 7

    Favorable safety and tolerability profile reported.

  • 8

    Investigational status with no current market approval.

Original Source(s)

EYP-1901 for Retinal Exudative Diseases

An overview of the current status of the EYP-1901 clinical trial program in wet AMD and DME, presented at Hawaiian Eye and Retina 2026

  • by Sumit Sharma

  • January 23, 2026

  • 5 min

Related Content

When the Kidney Meets the Retina

New study suggests potential causal link between kidney disease and AMD

  • January 22, 2026

  • 3 min
Coding Q&A: Coding Guidelines for Wet AMD

Proper use of ICD-10-CM codes ensures compliance and prompt payment.

Video: Reducing Injections in Wet AMD

Avni Finn, MD, and Diana V. Do, MD, discuss promising results from the DAVIO2 trial of EYP-1901.